At the American Epilepsy Society annual meeting, Dr. Barry S. Ticho discussed the effectiveness of zorevunersen in reducing seizures in patients with Dravet syndrome. Zorevunersen led to a 75% to 80% reduction in seizures, which is significant as it is the only antiseizure medication in the clinic with disease-modifying effects. Studies showed that zorevunersen, an antisense oligonucleotide, increased levels of NAV1.1 proteins in nerve cells, ultimately reducing seizure occurrence and related comorbidities. The treatment was well-tolerated, with the most significant effect seen with a 70 mg dose, leading to improvements in cognition and behavior within the first 9 months of treatment.
Source link
Health Information Management